Lonza Pharma & Biotech

	Building on a history of innovation in polymer science and capsule engineering, the Capsugel® brand, now part of Lonza, offers a product and services portfolio beneficial for Pharmaceutical and OTC customers alike. Capsugel® is the global leader in capsules, encapsulation technology, and designs. Their unique combination of science, engineering, formulation, and capsule expertise enables customers to optimize the bioavailability, targeted delivery, and overall performance of their products and services. Learn more about the benefits of partnering with Lonza Capsugel® and their full offerings by joining this informative webcast.

		The importance of choosing the right capsule during the development phase

		Discover new tools to help choose the right capsule during the development phase

		Explore value-added services aimed at cost reduction and improved efficiency

		Discover encapsulation tools that can help make the process to commercialization faster, easier and more successful

Julien Lamps, Product Manager, Capsule Delivery Solutions, Lonza Pharma & Biotech

	Mary Ellen Johnson, Product Manager, Capsule Delivery Solutions, Lonza Pharma & Biotech

Thursday, Mar. 12, 2020 at 11am EDT | 8am PDT | 3pm GMT | 4pm CET

	On demand available after airing until Mar. 12, 2021

Webcasts

Join us for an informative webcast on March 12th at 11am EDT as we discuss the full capabilities of the Lonza Capsugel® Products and Services Portfolio. Our offerings include high-quality capsules, both in gelatin and specialty polymers, a premier portfolio of equipment, unparalleled industry and regulatory knowledge, and more. 
Live: Thursday, Mar. 12, 2020 at 11am EDT | 8am PDT | 3pm GMT | 4pm CET
On demand available after airing until Mar. 12, 2021
Register free



Lonza Capsugel® – The Right Partner for Your Next Drug Development Project

	Oral administration of small molecules has become increasingly difficult due to a majority of new candidates demonstrating poor aqueous solubility. The bioavailability hurdle is made more challenging with the accelerated timelines, limited drug substance availability, and financial restrictions associated with many of today’s drug programs. This presentation discusses a proven model-based technology selection methodology for poorly soluble molecules and an integrated formulation approach to minimize first-in-human timelines. The role of API development and supply, solid state characterization, and rational bioavailability-technology selection will be presented. 

		Rational technology selection of bioavailability challenged molecules

		Methods for selecting high API loaded dosage forms

David Lyon, Ph.D.,Sr. Fellow, Research, Lonza Pharma & Biotech-Bend

 Wednesday, Oct. 23, 2019 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST

	On demand available after airing until Oct. 23, 2020

Oral administration of small molecules has become increasingly difficult due to a majority of new candidates demonstrating poor aqueous solubility. Dr. David Lyon will discuss a proven model-based technology selection methodology for poorly soluble molecules and an integrated formulation approach to minimize first-in-human timelines. 
Live: Wednesday, Oct. 23, 2019 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
On demand available after airing until Oct. 23, 2020
Register free



An Integrated Approach to Rapidly Delivering Bioavailability-Challenged Small Molecules to the Clinic

	Drug development based on potent compounds can be quite challenging. Crossing the boundary from small molecule to biologics into antibody-drug conjugate (ADC) territory adds levels of complexity.

	In this webcast, experts will elaborate on best practices and infrastructure requirements that facilitate accelerated timelines to clinic.

		The advantages of seamless integration of highly potent APIs, monoclonal antibodies, and ADC operations

		The impact of supporting integrated service offerings on expansion strategies

		ADC process scale-up from clinical manufacturing to commercial drug substance production

		A case study will review the development, rapid scaling, and commercial production of HPAPI drug substance

Maurits Janssen, PhD, Senior Director Head of Commercial Development, API, Lonza Pharma & Biotech

	Bernhard Stump, PhD, Head of Process Development Bioconjugates, Lonza Pharma & Biotech

Friday, Sept. 27, 2019 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST

	On demand available after airing until Sept. 27, 2020

Drug development based on potent compounds can be quite challenging. Crossing the boundary from small molecule to biologics into antibody-drug conjugate (ADC) territory adds levels of complexity. Learn more about infrastructure requirements and best practices.
Live: Friday, Sept. 27, 2019 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
On demand available after airing until Sept. 27, 2020 
Register free

APIs and ADCs: a journey through high potency

	Lonza provides integrated product development to our clients which includes our premier particle engineering capability through micronization, with capabilities from early-stage design through scale-up and commercial quantities.

	This webcast will provide an overview of the different size-reduction techniques for tailoring a particle size distribution. First, industry experts will provide an overview of milling and micronization technologies and equipment selection. They will then discuss the key findings of a case study on micronization process development of a highly potent API, including stress testing and solid state characterization, followed by scale-up on GMP industrial-scale with equipment customization.

		Micronization/milling, particle size, solid state characterization, synergies with engineering (equipment), overall micronization capabilities

		R&D, new product development (both drug substance and drug product), project leaders

Salvatore Mercuri, Ph.D., Head of R&D, Lonza Pharma & Biotech

	Andrea Della Bella, Ph.D., R&D Senior Scientist, Analytical Development, Lonza Pharma & Biotech

 Wednesday, Aug. 7, 2019 at 10am EDT | 9am CDT | 3pm BST | 4pm CEST

	On demand available after airing until Aug. 7, 2020

The objective of the webcast is to give an overview of the different size reduction techniques for tailoring particle size distribution. In particular, the speakers will focus on milling and micronization technologies and equipment selection. 
Live: Wednesday, Aug. 7, 2019 at 10am EDT | 9am CDT | 3pm BST | 4pm CEST
On demand available after airing until Aug. 7, 2020
Register free



Innovative Approaches to Tailoring Particle Size Distribution

 Enteric Capsule is a fully compliant capsule technology that simplifies drug enteric delivery implementation from early-stage development to commercial manufacturing. The pharmaceutical grades of cellulosic derivatives used in Capsugel

 Enteric capsules are approved and have extensive market precedence for use in providing enteric protection. They have been evaluated in-vitro and in-vivo across a number of compounds, which has proven full compliance with relevant European, Japanese and US Pharmacopeia monographs.

 Enteric capsules can be utilized to greatly simplify and accelerate prototype development and rapid in-vivo testing of products requiring targeted delivery to the upper GI tract:

		Eliminate coating system preparation and application steps

		Rapid screening and optimization of enteric performance

		Remove dependency of enteric functionality with process variability

		Obviate need for process development of the enteric coating step, process scale-up and validation

		Manufactured with pharmaceutical-grade cellulosic derivatives (HPMCAS, HPMC)

	Company name: Lonza Pharma & Biotech
	Website: 

www.capsugel.com/biopharmaceutical-products/vcaps-enteric-capsules

Articles

Due to the intrinsic enteric properties of Capsugel® Vcaps® Enteric, no coating step is needed. It means that this capsule is a ready-to-use solution that can help you in obtaining significant cost and time savings during pharmaceutical development or compounding.